• Subscribe
  • Webinars
  • White Papers
  • Buyer's Guide
  • PhotonicsNXT
  • Get Published!
    • Recent Quotes
    My Watchlist
    Indicators
    BioOptics Stock Watch
    Markets
    Stocks
    ETFs
    Tools
    Overview
    News
    Currencies
    International
    Treasuries

    Neurogene Inc. - Common Stock (NQ: NGNE )

    38.30 +1.51 (+4.10%)
    Streaming Delayed Price Updated: 4:00 PM EDT, Jul 9, 2024 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Price and Volume

    Detailed Quote
    Volume 79,036
    Open 36.55
    Bid (Size) 34.49 (1)
    Ask (Size) 42.17 (1)
    Prev. Close 36.79
    Today's Range 36.24 - 39.68
    52wk Range 12.49 - 53.00
    Shares Outstanding N/A
    Dividend Yield N/A
    Chart for (: )
    Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

    Top News

    More News
    Neurogene to Participate in BMO Genetic Medicines Summit
    From Neurogene Inc.
    Via Business Wire
    Neurogene Announces Addition to Russell 3000® Index
    From Neurogene Inc.
    Via Business Wire

    Performance

    YTD
    +92.75%
    +92.75%
    1 Month
    +2.54%
    +2.54%
    3 Month
    -7.98%
    -7.98%
    6 Month
    +45.38%
    +45.38%
    1 Year
    +153.64%
    +153.64%

    More News

    Read More
    12 Health Care Stocks Moving In Thursday's Pre-Market Session
    Via Benzinga
    Why Quantum Shares Are Trading Lower By 45%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
    Via Benzinga
    MicroMarvel Neurogene Challenges Big Pharma
    Via Talk Markets
    Neurogene Announces First Patient Dosed in High-Dose Cohort of NGN-401 Gene Therapy Clinical Trial for Rett Syndrome
    From Neurogene Inc.
    Via Business Wire
    Neurogene to Participate in Upcoming Conferences
    From Neurogene Inc.
    Via Business Wire
    Neurogene Announces NGN-401 Gene Therapy for Rett Syndrome Selected by FDA for START Pilot Program
    From Neurogene Inc.
    Via Business Wire
    NGNE Stock Earnings: Neurogene Beats EPS for Q1 2024
    Via InvestorPlace
    Neurogene Reports First Quarter 2024 Financial Results and Highlights Recent Updates
    From Neurogene Inc.
    Via Business Wire
    Neurogene Presents Favorable Safety Data from Phase 1/2 Trial of NGN-401 Gene Therapy for Rett Syndrome during ASGCT Annual Meeting
    From Neurogene Inc.
    Via Business Wire
    Neurogene Announces Upcoming Presentation of Safety Data from Phase 1/2 Trial of NGN-401 Gene Therapy for Rett Syndrome at ASGCT Meeting
    From Neurogene Inc.
    Via Business Wire
    7 A-Rated Aggressive Biotech Stocks to Bet On in 2024
    Via InvestorPlace
    Neurogene Reports Fourth Quarter and Full Year 2023 Financial Results and Highlights Recent Updates
    From Neurogene Inc.
    Via Business Wire
    Neurogene Announces Expansion and Plans for More Rapid Patient Enrollment of Rett Syndrome Gene Therapy Clinical Trial
    From Neurogene Inc.
    Via Business Wire
    Neurogene to Participate in Upcoming Investor Conferences
    From Neurogene Inc.
    Via Business Wire
    Neurogene Announces Appointment of Julie Jordan, M.D., as Chief Medical Officer
    From Neurogene Inc.
    Via Business Wire
    Neurogene Announces Business Update and 2024 Outlook
    From Neurogene Inc.
    Via Business Wire
    Data & News supplied by www.cloudquote.io
    Stock quotes supplied by Barchart
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the following
    Privacy Policy and Terms and Conditions.